Are clinical trials safe?

Yes. Every study on QualifiedStudies is reviewed and approved by an Institutional Review Board (IRB) and conducted under FDA regulations. Research sites are HIPAA-covered entities, and you can withdraw at any time for any reason.

Do I get paid to participate in a clinical trial?

Most studies offer compensation for your time and travel. The amount varies by study length and visit schedule, and is disclosed up front before you enroll.

Is my health information kept private?

Yes. Your information is encrypted, never sold, and only shared with the specific research site you choose to apply to. Our handling of your data is governed by our Consumer Health Data Privacy Policy; the research sites you're matched with are HIPAA-covered entities.

How do I qualify for a clinical trial?

Take our free 60-second eligibility quiz. Enter your ZIP code, condition, and a few health details, and we'll match you with research sites near you that are actively enrolling participants.

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

NCT ID: NCT07817251
Registry status: Not yet recruiting
Study type: Not specified in the registry data
Phase: Phase 3
Sponsor: Novo Nordisk A/S

Overview

ClinicalTrials.gov lists this study as Not yet recruiting.

Enrollment: 210 participants (Estimated).

What is being studied

No interventions are listed in the registry data.

Who may be eligible

Ages: Not specified in the registry data
Sex: Not specified in the registry data
Healthy volunteers accepted: No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Diagnosed with type 2 diabetes mellitus (T2DM) greater than or equal to (≥) 180 days before screening. * Stable once-weekly dose ≥ 90 days before screening of branded s.c. semaglutide. Branded semaglutide s.c. includes Ozempic and Wegovy. Participants on compounded semaglutide are ineligible. * Not on treatment with oral antidiabetic drugs or on stable daily dose(s) ≥ 90 days before screening of any of the following antidiabetic drug(s) or combination regimen at effective or maximum tolerated dose (MTD) as judged by the investigator: metformin and/or sodiumglucose co-transporter-2 (SGLT2) inhibitor. * Glycated haemoglobin (HbA1c) 6.5-10.5 percentage (%) (48-91 millimoles per mole \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening. * Body mass index (BMI) ≥ 25 kilograms per square meter (kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening. Exclusion criteria: * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method from screening. * Renal impairment with estimated glomerular filtration rate (eGFR) less than (\<) 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) as determined by central laboratory at screening. * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * A self-reported change in body weight \> 5% within 90 days before screening irrespective of medical records. * Use of personal continuous glucose monitoring (CGM) devices. Participants currently using personal CGM devices must discontinue use prior to screening and throughout study participation.

Study locations

40 study locations are listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: United States

Arizona, United States: 1
California, United States: 8
Connecticut, United States: 1
Florida, United States: 5
Hawaii, United States: 1
Illinois, United States: 1
Iowa, United States: 1
Kansas, United States: 2
Michigan, United States: 1
Nevada, United States: 1
New Mexico, United States: 1
North Carolina, United States: 2
Ohio, United States: 1
Tennessee, United States: 1
Texas, United States: 9
Utah, United States: 3
Virginia, United States: 1

Sample of listed locations

Gilbert Center For Family Medicine — Gilbert, Arizona, 85296, United States — Site recruitment status not specified in the registry data
Ark Clinical Research — Fountain Valley, California, 92708, United States — Site recruitment status not specified in the registry data
Thrive Clinical Research Group — Glendora, California, 91740, United States — Site recruitment status not specified in the registry data
Scripps Whittier Diabetes Inst — La Jolla, California, 92037, United States — Site recruitment status not specified in the registry data
Downtown LA Res Ctr. Inc. — Los Angeles, California, 90017, United States — Site recruitment status not specified in the registry data
Valley Clinical Trials, Inc. — Northridge, California, 91325, United States — Site recruitment status not specified in the registry data
Dream Team Clinical Research — Pomona, California, 91767, United States — Site recruitment status not specified in the registry data
Clinical Trials Research_Sacramento — Sacramento, California, 95821, United States — Site recruitment status not specified in the registry data
Linda Vista Health Care Ctr — San Diego, California, 92111, United States — Site recruitment status not specified in the registry data
Chase Medical Research LLC — Waterbury, Connecticut, 06708, United States — Site recruitment status not specified in the registry data
Northeast Research Institute — Fleming Island, Florida, 32003, United States — Site recruitment status not specified in the registry data
AGA Clinical Trial — Hialeah, Florida, 33012, United States — Site recruitment status not specified in the registry data
Adult Medicine of Lake County, Inc — Mt. Dora, Florida, 32757, United States — Site recruitment status not specified in the registry data
Optimal Research Sites — Orange City, Florida, 32763, United States — Site recruitment status not specified in the registry data
Metabolic Research Institute Inc — West Palm Beach, Florida, 33401, United States — Site recruitment status not specified in the registry data
East West Med Res Inst — Honolulu, Hawaii, 96814, United States — Site recruitment status not specified in the registry data
Endeavor Health — Skokie, Illinois, 60077, United States — Site recruitment status not specified in the registry data
Iowa Diabetes & Endo Res Ctr — West Des Moines, Iowa, 50266, United States — Site recruitment status not specified in the registry data
Alliance for Multispecialty Research — Newton, Kansas, 67114, United States — Site recruitment status not specified in the registry data
Cotton O'Neil Diabetes & Endocrinology — Topeka, Kansas, 66606, United States — Site recruitment status not specified in the registry data
Northern Pines Hlth Ctr, PC — Buckley, Michigan, 49620, United States — Site recruitment status not specified in the registry data
Palm Research Center Inc-Vegas — Las Vegas, Nevada, 89128, United States — Site recruitment status not specified in the registry data
Albuquerque Clinical Trials Inc. — Albuquerque, New Mexico, 87102, United States — Site recruitment status not specified in the registry data
PharmQuest Life Sciences LLC — Greensboro, North Carolina, 27408, United States — Site recruitment status not specified in the registry data
Accellacare Wilmington — Wilmington, North Carolina, 28401, United States — Site recruitment status not specified in the registry data

Study details

Start date: September 16, 2026
Primary completion date: June 9, 2027
First posted: September 14, 2026

Source and update information

Source: ClinicalTrials.gov
NCT ID: NCT07817251
Registry last updated: September 14, 2026
QualifiedStudies registry data refreshed: September 21, 2026

View NCT07817251 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Diabetes (Type II) studies | Clinical trial FAQ